Back

A novel dual-action insulin secreting and natriuretic peptide, CRRL 101, a potential therapy for diabetic cardiomyopathy

12 May 2024 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 9 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ivan Nunzio Isaia

Mayo Clinic, Rochester (United States of America)

7 More presentations in this session

Presentation thumbnail
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.
Doctor M. Sweeney (London, GB)
Abstract Slides Video
Presentation thumbnail
Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.
Miss H. Hauksdottir (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
The effect of an incentive billing code on heart failure management in primary care: a population-based study
Doctor S. Zhou (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
Doctor I. Fumarulo (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Persistence of autoantibodies directed against the beta-1-adrenoceptor in patients with heart failure after treatment with BC 007 (Rovunaptabin). Results of a phase IIa study.
Associate Professor M. Zdravkovic (Belgrade, RS)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - treatment 9

The Event

Event poster

Heart Failure 2024

12 May 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Potential treatments
thumbnail
Congress Presentation
ACEI plus GLP1-RA or SGLT2i, as well as ARNI, exerted distinct protective effects against diabetic nephropathy and heart failure with preserved ejection fraction in eNOS-/- dbdb mice.
thumbnail
Congress Presentation
Diabetic CMP: new approaches on the horizon?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources